CECMED has approved the Soberana 02 vaccine for use in the pediatric population. Photo: Atalayar
The Center for State Control of Medicines, Equipment and Medical Devices (CECMED) approved the emergency use of the SOBERANA 02 in the pediatric population aged 2 to 18 years of age. The manufacturer of the vaccine, the Finlay Vaccine Institute (IFV), had applied for approval.
CECMED approved the Soberana 02 vaccine based on the requirements of quality, safety, and immunogenicity for this group.
They based the approval on the trial results of an application of a two-dose schedule in children aged 3 to 18 years old and another in persons aged 19 to 80 years.
The results obtained in the clinical trials were superior in all variables in the group aged 19 to 80 years. It showed similar results in young adults aged 19 to 29 years.
The safety profile showed similar results between the groups compared. They include children from age 2 in the approval, based on information provided by the IFV.
CECMED carried out inspections of the clinical testing sites where the trials took place verifying compliance with Good Clinical Practices.
From our staff writers and editors.
In a move with both economic and geopolitical significance, Cuba has officially joined the New…
Cuba’s tourism sector, long a vital part of the island’s economy, is experiencing mixed fortunes…
Cuba took center stage at the 17th BRICS 2025 in Rio de Janeiro this weekend,…
Cuba has confirmed the 41st edition of the Havana International Fair (FIHAV 2025) will take…
WestJet CEO Alexis von Hoensbroech met Wednesday with Cuban President Miguel Díaz-Canel in Havana, a high-level meeting…
Cuba is ramping up efforts to address energy shortages through the expansion of photovoltaic solar…